Yamane K, Yamamoto K, Yoshikawa Y, Sasazuki T
Department of Genetics, Faculty of Dentistry, Kyushu University, Fukuoka, Japan.
Clin Exp Immunol. 1996 Jan;103(1):141-8. doi: 10.1046/j.1365-2249.1996.00892.x.
Previous studies have shown that a transgenic I-E alpha gene, the mouse homologue of human DR alpha gene, prevents the development of insulitis and hence of diabetes in NOD mice. To investigate the mechanism of this prevention, we generated two strains of NOD mice expressing DR alpha E beta molecule: DR alpha-24-NOD expressing DR alpha E beta molecule on thymic epithelial cells (TEC) and bone marrow-derived cells (BDC), and DR alpha-30-NOD expressing DR alpha E beta molecule only on the TEC, and these mice were monitored for disease development. Because the DR alpha E beta molecule reconstituted I-E controlled immune regulation, it would become clear which cell type, TEC or BDC, was responsible for the I-E-mediated disease protection. To our surprise, however, DR alpha-24-NOD developed insulitis and diabetes comparably to non-transgenic littermates. This suggested that the difference in structure between DR alpha and E alpha molecules contributed to the difference in preventive effect on the development of insulitis and diabetes between DR alpha-24-NOD and E alpha-NOD. In an analysis of the T cell proliferative responses to glutamic acid decarboxylase (GAD) 65-derived peptides which were known to be diabetogenic autoantigens, it was shown that DR alpha-24-NOD and NOD acquired comparable level of T cell response to GAD 509-528 but 5-10-fold higher response was observed in E alpha-NOD. This suggested that I-ANOD and E alpha E beta NOD molecules could present GAD 509-528 peptide to T cells, while DR alpha E beta NOD could not. Furthermore, T cells from DR alpha transgenic mice showed proliferative response to antigen-presenting cells from E alpha transgenic mice in primary mixed lymphocyte reaction. This also suggested that the E alpha E beta molecule does differ in structure and peptide binding from the DR alpha E beta molecule. Present data suggested a possibility that the T cell repertoire selection, or the T cell response to GAD 65 and/or other unknown antigens specifically mediated by I-E molecule, may contribute to the prevention of disease development in E alpha-NOD.
先前的研究表明,转基因I-Eα基因(人类DRα基因的小鼠同源物)可预防NOD小鼠发生胰岛炎及糖尿病。为研究这种预防机制,我们培育了两株表达DRαEβ分子的NOD小鼠:DRα-24-NOD在胸腺上皮细胞(TEC)和骨髓来源细胞(BDC)上表达DRαEβ分子,DRα-30-NOD仅在TEC上表达DRαEβ分子,并对这些小鼠的疾病发展情况进行监测。由于DRαEβ分子重建了I-E控制的免疫调节,因此可以明确是哪种细胞类型(TEC还是BDC)负责I-E介导的疾病保护。然而,令我们惊讶的是,DRα-24-NOD发生胰岛炎和糖尿病的情况与非转基因同窝小鼠相当。这表明DRα和Eα分子之间的结构差异导致了DRα-24-NOD和Eα-NOD在预防胰岛炎和糖尿病发展方面的效果差异。在对已知为致糖尿病自身抗原的谷氨酸脱羧酶(GAD)65衍生肽的T细胞增殖反应分析中,发现DRα-24-NOD和NOD对GAD 509-528的T细胞反应水平相当,但在Eα-NOD中观察到的反应高5-10倍。这表明I-A NOD和EαEβNOD分子可以将GAD 509-528肽呈递给T细胞,而DRαEβNOD则不能。此外,在初次混合淋巴细胞反应中,来自DRα转基因小鼠的T细胞对来自Eα转基因小鼠的抗原呈递细胞表现出增殖反应。这也表明EαEβ分子在结构和肽结合方面与DRαEβ分子不同。目前的数据表明,T细胞库选择,或I-E分子特异性介导的T细胞对GAD 65和/或其他未知抗原的反应,可能有助于预防Eα-NOD中的疾病发展。